



## Curriculum Vitae

Personal information **Sara Antonia Rieke**

### Work experience

---

- 09.2024 – present: **Pharmacovigilance assessor**, Paul Ehrlich Institute, Germany, Assessment
- 04.2024-07.2024: **Traineeship**: Global Patient Safety: PV System and QPPV, Merck Healthcare KGaA, Germany, supporting Partnership management and QPPV team
- 06.2019-07.2019: **Student assistant** at the Böhringer Ingelheim Foundation, Germany
- 10.2018 – 2.2019: **Student assistant** at the TU Darmstadt, Germany, Research Group: System Biology of the Stress Response
- 10.2016 – 12.2017: **Student assistant** at the Julius Kühn Institute, Darmstadt, Germany, Department: Histopathology

### Education and training

---

- 08.2019 - present: **PhD** (Dr. rer. nat.), University Hospital Frankfurt, Medical Clinic 2, Hematology/Oncology and Darmstadt University of Technology, Germany, cancer research
- 12.2023-07.2024: Health Academy Hessen (HGA), Germany, Professional development, **Clinical Project Management** (training in Good Clinical Practice, Biological and medical pharmaceutical research, Clinical Research (study management / study assistance), Good Manufacturing Practice, Life Sciences Project and Process Management, Process management, Quality management officers incl. soft skills training, Quality officers with TÜV Rheinland-certified qualification, Quality assurance (pharma / medical technology / biotech))
- 10.2015 - 06.2018: Darmstadt University of Technology, Germany, **Master of Science** (Technical Biology)
- 10.2012 - 10.2015: Darmstadt University of Technology, Germany, **Bachelor of Science** (Biology)

### Additional information

---

#### Publications

- Sheng, C., Mendler, I., Rieke, S., ... Loewer, A. (2019). PCNA-Mediated Degradation of p21 Coordinates the DNA Damage Response and Cell Cycle Regulation in Individual Cells. *Cell reports*, 27(1), 48-58.
- Wilke, A. C., Doebele, C., Zindel, A., Lee, K. S., Rieke, S. A., ... & Oellerich, T. (2022). SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. *Blood, The Journal of the American Society of Hematology*, 139(4), 538-553.
- Phelan, J. D., Scheich, S., Choi, J., Wright, G. W., Häupl, B., Young, R. M., Rieke, S.A., ... & Oellerich, T. (2024). Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. *Cancer Cell*, 42(2), 238-252.

#### Projects

#### Memberships

#### Other Relevant Information